Belapectin – Medxy AI

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis

By MedXY 06/01/2026

This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.

Clinical Updates news

Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics

By MedXY 06/01/2026

This review synthesizes clinical evidence for belapectin in MASH cirrhosis, focusing on its efficacy in preventing esophageal varices as demonstrated in the NAVIGATE trial and early phase 2b data.

Clinical Updates news

Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial

By MedXY 06/01/2026

This review synthesizes clinical evidence on belapectin, a galectin-3 inhibitor, highlighting its potential to reduce the incidence of esophageal varices in patients with MASH-related cirrhosis and portal hypertension, particularly at the 2 mg/kg dosage.